MANKIND PHARMA
|
MANKIND PHARMA Last 5 Year Income Statement History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| INCOME : | |||||
| Gross Sales | ₹10,677 Cr | ₹910,563 Cr | ₹8,071 Cr | ₹647 Cr | ₹61,007 Cr |
| Sales | ₹10,607 Cr | ₹904,838 Cr | ₹8,067 Cr | ₹646 Cr | ₹60,924 Cr |
| Job Work/ Contract Receipts | ₹21 Cr | ₹3,421 Cr | - | - | - |
| Processing Charges / Service Income | ₹49 Cr | ₹2,304 Cr | ₹3.46 Cr | ₹0.25 Cr | ₹16 Cr |
| Revenue from property development | - | - | - | - | - |
| Other Operational Income | - | - | - | - | ₹68 Cr |
| Less: Excise Duty | - | - | - | - | - |
| Net Sales | ₹10,260 Cr | ₹874,943 Cr | ₹7,782 Cr | ₹621 Cr | ₹58,719 Cr |
| EXPENDITURE : | |||||
| Increase/Decrease in Stock | ₹-54 Cr | ₹29,074 Cr | ₹-450 Cr | ₹-25 Cr | ₹-105 Cr |
| Raw Material Consumed | ₹3,252 Cr | ₹262,290 Cr | ₹2,871 Cr | ₹203 Cr | ₹18,885 Cr |
| Opening Raw Materials | ₹414 Cr | ₹39,862 Cr | ₹284 Cr | ₹25 Cr | ₹1,605 Cr |
| Purchases Raw Materials | ₹1,837 Cr | ₹182,940 Cr | ₹2,173 Cr | ₹141 Cr | ₹13,699 Cr |
| Closing Raw Materials | ₹409 Cr | ₹41,436 Cr | ₹399 Cr | ₹28 Cr | ₹2,331 Cr |
| Other Direct Purchases / Brought in cost | ₹1,410 Cr | ₹80,924 Cr | ₹814 Cr | ₹65 Cr | ₹5,912 Cr |
| Other raw material cost | - | - | - | - | - |
| Power & Fuel Cost | ₹125 Cr | ₹10,896 Cr | ₹103 Cr | ₹8.25 Cr | ₹800 Cr |
| Electricity & Power | ₹125 Cr | ₹10,896 Cr | ₹103 Cr | ₹8.25 Cr | ₹800 Cr |
| Oil, Fuel & Natural gas | - | - | - | - | - |
| Coals etc | - | - | - | - | - |
| Other power & fuel | - | - | - | - | - |
| Employee Cost | ₹2,261 Cr | ₹191,847 Cr | ₹1,621 Cr | ₹142 Cr | ₹13,355 Cr |
| Salaries, Wages & Bonus | ₹2,094 Cr | ₹178,801 Cr | ₹1,515 Cr | ₹133 Cr | ₹12,714 Cr |
| Contributions to EPF & Pension Funds | ₹100 Cr | ₹8,896 Cr | ₹74 Cr | ₹5.87 Cr | ₹429 Cr |
| Workmen and Staff Welfare Expenses | ₹19 Cr | ₹2,191 Cr | ₹15 Cr | ₹1.16 Cr | ₹89 Cr |
| Other Employees Cost | ₹47 Cr | ₹1,959 Cr | ₹17 Cr | ₹1.54 Cr | ₹123 Cr |
| Other Manufacturing Expenses | ₹173 Cr | ₹15,057 Cr | ₹160 Cr | ₹14 Cr | ₹1,092 Cr |
| Sub-contracted / Out sourced services | - | - | - | - | - |
| Processing Charges | - | - | - | - | - |
| Repairs and Maintenance | ₹43 Cr | ₹3,887 Cr | ₹37 Cr | ₹2.70 Cr | ₹250 Cr |
| Packing Material Consumed | - | - | - | - | - |
| Other Mfg Exp | ₹130 Cr | ₹11,170 Cr | ₹124 Cr | ₹11 Cr | ₹842 Cr |
| General and Administration Expenses | ₹939 Cr | ₹100,080 Cr | ₹656 Cr | ₹45 Cr | ₹4,390 Cr |
| Rent , Rates & Taxes | ₹89 Cr | ₹13,196 Cr | ₹84 Cr | ₹5.86 Cr | ₹609 Cr |
| Insurance | ₹18 Cr | ₹1,544 Cr | ₹14 Cr | ₹1.04 Cr | ₹84 Cr |
| Printing and stationery | ₹9.50 Cr | ₹1,042 Cr | ₹7.02 Cr | ₹0.53 Cr | ₹43 Cr |
| Professional and legal fees | ₹203 Cr | ₹16,935 Cr | ₹88 Cr | ₹4.94 Cr | ₹308 Cr |
| Traveling and conveyance | ₹378 Cr | ₹49,605 Cr | ₹358 Cr | ₹27 Cr | ₹2,695 Cr |
| Other Administration | ₹242 Cr | ₹17,758 Cr | ₹105 Cr | ₹5.77 Cr | ₹651 Cr |
| Selling and Distribution Expenses | ₹924 Cr | ₹63,811 Cr | ₹708 Cr | ₹59 Cr | ₹4,267 Cr |
| Advertisement & Sales Promotion | ₹601 Cr | ₹37,367 Cr | ₹452 Cr | ₹39 Cr | ₹2,553 Cr |
| Sales Commissions & Incentives | ₹198 Cr | ₹18,049 Cr | ₹174 Cr | ₹14 Cr | ₹1,244 Cr |
| Freight and Forwarding | ₹125 Cr | ₹8,367 Cr | ₹82 Cr | ₹6.15 Cr | ₹470 Cr |
| Handling and Clearing Charges | - | - | - | - | - |
| Other Selling Expenses | ₹0.15 Cr | ₹28 Cr | ₹0.22 Cr | ₹0.02 Cr | - |
| Miscellaneous Expenses | ₹125 Cr | ₹11,696 Cr | ₹121 Cr | ₹11 Cr | ₹1,587 Cr |
| Bad debts /advances written off | ₹4.62 Cr | ₹464 Cr | ₹4.92 Cr | ₹0.06 Cr | ₹6.12 Cr |
| Provision for doubtful debts | ₹7.96 Cr | ₹915 Cr | ₹9.65 Cr | ₹0.11 Cr | ₹59 Cr |
| Losson disposal of fixed assets(net) | - | - | ₹3.74 Cr | ₹0.30 Cr | - |
| Losson foreign exchange fluctuations | - | - | - | - | ₹10 Cr |
| Losson sale of non-trade current investments | - | - | - | - | - |
| Other Miscellaneous Expenses | ₹112 Cr | ₹10,317 Cr | ₹103 Cr | ₹10 Cr | ₹1,511 Cr |
| Less: Expenses Capitalised | - | - | - | - | - |
| Total Expenditure | ₹7,745 Cr | ₹684,750 Cr | ₹5,791 Cr | ₹457 Cr | ₹44,272 Cr |
| Operating Profit (Excl OI) | ₹2,515 Cr | ₹190,193 Cr | ₹1,991 Cr | ₹165 Cr | ₹14,447 Cr |
| Other Income | ₹280 Cr | ₹12,857 Cr | ₹196 Cr | ₹17 Cr | ₹1,038 Cr |
| Interest Received | ₹40 Cr | ₹1,276 Cr | ₹13 Cr | ₹3.83 Cr | ₹129 Cr |
| Dividend Received | - | ₹0.24 Cr | ₹0.00 Cr | ₹0.04 Cr | ₹43 Cr |
| Profit on sale of Fixed Assets | ₹0.48 Cr | ₹166 Cr | - | - | ₹19 Cr |
| Profits on sale of Investments | - | - | - | - | ₹351 Cr |
| Provision Written Back | ₹2.48 Cr | ₹415 Cr | ₹34 Cr | ₹0.77 Cr | - |
| Foreign Exchange Gains | ₹8.44 Cr | ₹1,041 Cr | ₹8.85 Cr | ₹0.05 Cr | - |
| Others | ₹229 Cr | ₹9,958 Cr | ₹140 Cr | ₹12 Cr | ₹496 Cr |
| Operating Profit | ₹2,795 Cr | ₹203,050 Cr | ₹2,187 Cr | ₹182 Cr | ₹15,485 Cr |
| Interest | ₹34 Cr | ₹4,576 Cr | ₹60 Cr | ₹2.12 Cr | ₹232 Cr |
| InterestonDebenture / Bonds | - | - | - | - | - |
| Interest on Term Loan | ₹19 Cr | ₹3,605 Cr | ₹16 Cr | ₹1.55 Cr | ₹137 Cr |
| Intereston Fixed deposits | - | - | - | - | - |
| Bank Charges etc | ₹6.42 Cr | ₹130 Cr | ₹4.02 Cr | ₹0.19 Cr | ₹17 Cr |
| Other Interest | ₹8.71 Cr | ₹842 Cr | ₹40 Cr | ₹0.38 Cr | ₹78 Cr |
| PBDT | ₹2,761 Cr | ₹198,473 Cr | ₹2,127 Cr | ₹180 Cr | ₹15,253 Cr |
| Depreciation | ₹378 Cr | ₹32,592 Cr | ₹167 Cr | ₹12 Cr | ₹991 Cr |
| Profit Before Taxation & Exceptional Items | ₹2,383 Cr | ₹165,881 Cr | ₹1,960 Cr | ₹168 Cr | ₹14,262 Cr |
| Exceptional Income / Expenses | - | - | - | - | - |
| Profit Before Tax | ₹2,398 Cr | ₹167,124 Cr | ₹1,975 Cr | ₹169 Cr | ₹14,377 Cr |
| Provision for Tax | ₹457 Cr | ₹36,156 Cr | ₹522 Cr | ₹40 Cr | ₹3,816 Cr |
| Current Income Tax | ₹495 Cr | ₹33,199 Cr | ₹451 Cr | ₹39 Cr | ₹4,084 Cr |
| Deferred Tax | ₹-31 Cr | ₹4,117 Cr | ₹49 Cr | ₹0.24 Cr | ₹-327 Cr |
| Other taxes | ₹-7.22 Cr | ₹-1,160 Cr | ₹21 Cr | ₹0.14 Cr | ₹59 Cr |
| Profit After Tax | ₹1,941 Cr | ₹130,968 Cr | ₹1,453 Cr | ₹129 Cr | ₹10,561 Cr |
| Extra items | ₹0.98 Cr | - | - | - | - |
| Minority Interest | ₹-29 Cr | ₹-2,782 Cr | ₹-19 Cr | ₹-2.76 Cr | ₹-257 Cr |
| Share of Associate | - | - | - | - | - |
| Other Consolidated Items | - | - | - | - | - |
| Consolidated Net Profit | ₹1,913 Cr | ₹128,186 Cr | ₹1,433 Cr | ₹127 Cr | ₹10,304 Cr |
| Adjustments to PAT | - | - | - | - | - |
| Profit Balance B/F | ₹8,012 Cr | ₹673,519 Cr | ₹5,304 Cr | ₹407 Cr | ₹34,076 Cr |
| Appropriations | ₹9,925 Cr | ₹801,705 Cr | ₹6,737 Cr | ₹533 Cr | ₹44,380 Cr |
| General Reserves | - | - | - | - | - |
| Proposed Equity Dividend | - | - | - | - | - |
| Corporate dividend tax | - | - | - | - | - |
| Other Appropriation | ₹6.27 Cr | ₹485 Cr | ₹1.80 Cr | ₹2.74 Cr | ₹2,484 Cr |
| Equity Dividend % | - | - | - | - | ₹310.00 |
| Earnings Per Share | ₹47.75 | ₹32.00 | ₹35.78 | ₹31.59 | ₹25.72 |
| Adjusted EPS | ₹47.75 | ₹32.00 | ₹35.78 | ₹31.59 | ₹25.72 |
Compare Income Statement of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹92,667.4 Cr | 1.4% | -6.9% | -15.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹423,171.0 Cr | 3.5% | 6.2% | -4.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹173,172.0 Cr | -2.7% | -0.7% | 11% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹129,176.0 Cr | 0.6% | 9.1% | 19.7% | Stock Analytics | |
| CIPLA | ₹124,094.0 Cr | 1.2% | -1.4% | -4.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,869.0 Cr | 3.9% | 0.6% | -3.7% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | 1.4% |
-6.9% |
-15.2% |
| SENSEX | 1.7% |
3.6% |
6.9% |
You may also like the below Video Courses